Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice.

Purified populations of natural killer (NK) cells were obtained from mice with severe combined immune deficiency (SCID). SCID spleen cells were cultured and activated with recombinant human interleukin-2 (rhIL-2) in vitro. The activated NK cells were then transferred with syngeneic BALB/c bone marrow cells (BMC) and rhIL-2 into lethally irradiated syngeneic recipients to determine their effect on long-term hematopoietic reconstitution. On analysis, the transfer of rhIL-2-activated NK cells along with BMC resulted in significant increases in splenic and BM hematopoietic progenitor cells when compared with those for mice not receiving NK cells. Histologic and flow cytometric analysis showed a marked increase in granulocytic and megakaryocytic lineage cells present in the spleens of the mice receiving activated NK cells. Analysis of the peripheral blood indicated that the transfer of activated NK cells with BMC also significantly improved platelet and total white blood cell counts, with increases in segmented neutrophils. Erythroid recovery was not affected. Finally, lethally irradiated mice receiving activated NK cells and rhIL-2 along with limiting numbers of syngeneic BMC showed a marked increase in survival rate. These results show that the use of populations enriched for activated NK cells after syngeneic BM transplantation (BMT) has a profound enhancing effect on engraftment primarily affecting megakaryocytic and granulocytic cell reconstitution. Therefore, the transfer of activated NK cells and rhIL-2 may be of clinical use to promote hematopoietic reconstitution after BMT.

[1]  J. Armitage,et al.  Reviews and Notes: Oncology: High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells , 1992, Annals of Internal Medicine.

[2]  D. Williams,et al.  Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. , 1993, Blood.

[3]  A. Mazumder,et al.  LYMPHOKINE‐ACTIVATED KILLER CELLS IN AUTOLOGOUS BONE MARROW TRANSPLANTATION EVIDENCE AGAINST INHIBITION OF ENGRAFTMENT IN VIvo , 1992, Transplantation.

[4]  D. Longo,et al.  Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. , 1992, Blood.

[5]  W. Urba,et al.  The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Longo,et al.  Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. , 1992, Journal of immunology.

[7]  H. Gadner,et al.  A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. , 1992, Blood.

[8]  W. Murphy,et al.  Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility‐1 antigen‐specific bone marrow rejection in vivo , 1990, European journal of immunology.

[9]  L. Barnett,et al.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.

[10]  M. K. Warren,et al.  Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. , 1990, The Journal of clinical investigation.

[11]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[12]  T. Sayers,et al.  Differing Roles for Interleukin 2 and Interferon γ in the Augmentation of Mouse Peritoneal Natural Killer Cell Activity in vivo , 1989 .

[13]  T. Hirano,et al.  Interleukin-6 is a potent thrombopoietic factor in vivo in mice. , 1989, Blood.

[14]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[15]  W. Kuziel,et al.  T cell receptor genes do not rearrange or express functional transcripts in natural killer cells of scid mice. , 1987, Journal of immunology.

[16]  藤盛 好啓 Effect of lymphokine-activated killer cell fraction on the development of human hematopoietic progenitor cells , 1987 .

[17]  R. Welsh,et al.  Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo , 1985, The Journal of experimental medicine.

[18]  R. Herberman,et al.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells , 1975, International journal of cancer.